Vaxcyte (5VA) Price & Analysis

3 Followers

5VA Stock Chart & Stats

€53.00

-€0.20(-0.41%)

At close: Jul 28 4:00 PM EDT

€53.00

-€0.20(-0.41%)

Day’s Range― - ―

52-Week Range€33.20 - €76.50

Previous CloseN/A

Volume0.00

Average Volume (3M)10.00

Market Cap

€8.87B

Enterprise Value€7.03B

Total Cash (Recent Filing)€1.49B

Total Debt (Recent Filing)€115.44M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Nov 09, 2026

EPS Estimate

-1.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.64

Shares Outstanding148,805,280

10 Day Avg. Volume17

30 Day Avg. Volume10

Financial Highlights & Ratios

PEG Ratio-0.17

Price to Book (P/B)2.34

Price to Sales (P/S)0.00

P/FCF Ratio-9.38

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€105.77

Price Target Upside99.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-7.61

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Positive Phase 3 VAX-31 ResultsSuccessful pivotal data materially improves Vaxcyte’s probability of advancing VAX-31 toward approval. Meeting immunogenicity and safety endpoints against established vaccines supports regulatory credibility, strengthens the potential product profile, and creates a clearer path toward future commercialization.

Broad Pneumococcal CoverageThe candidate’s 31-valent design and broad serotype response could address coverage gaps that remain with current adult pneumococcal vaccines. If confirmed in later trials and accepted by regulators, this differentiation may support durable clinical relevance and competitive positioning.

Strong Balance Sheet And Low LeverageLow leverage and a substantial equity base provide financial flexibility while Vaxcyte funds late-stage development. This balance-sheet strength can help sustain clinical execution and regulatory preparation, reducing immediate dependence on debt despite the company’s significant operating cash requirements.

Bears Say

Pre-commercial Business With No Product RevenueVaxcyte has not yet demonstrated recurring commercial revenue, so its economic model remains dependent on successful development, approval, and launch of vaccine candidates. Until that transition occurs, operating performance cannot be supported by product sales or established commercial cash generation.

Accelerating Cash BurnRapidly worsening cash consumption increases the amount of capital required to advance VAX-31 and other programs. Persistent negative operating and free cash flow could reduce financial flexibility over time, particularly if development spending remains elevated before commercial revenue begins.

Dependence On External FinancingThe large equity and convertible-note offerings highlight reliance on capital markets to fund ongoing operations rather than internally generated cash. Repeated financing may increase dilution or future obligations, while access and terms can become important constraints during extended pre-commercial development.

Vaxcyte News

AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing...

2d ago

AZN

MRK

Vaxcyte 7.412M share Spot Secondary priced at $64.00

BTIG, Jefferies, Leerink, BofA, Goldman Sachs and Evercore ISI acted as joint book running managers for the offering....

2d ago

PCVX

Vaxcyte falls -11.3%

Vaxcyte (PCVX) is down -11.3%, or -$8.32 to $65.50. Published first on TheFly – the ultimate source for...

3d ago

PCVX

Vaxcyte price target raised to $146 from $130 at BofA

BofA raised the firm’s price target on Vaxcyte (PCVX) to $146 from $130 and keeps a Buy rating...

3d ago

PCVX

Vaxcyte files to sell $500M of common stock, $500M of convertible senior notes

Vaxcyte (PCVX) announced that it has commenced underwritten public offerings of $500M of its common stock and pre-funded...

4d ago

PCVX

Vaxcyte price target raised to $122 from $110 at Needham

Needham raised the firm’s price target on Vaxcyte (PCVX) to $122 from $110 and keeps a Buy rating...

4d ago

PCVX

Midday Fly By: Schneider to buy PTC, C.H. Robinson to acquire RXO

The major averages were mixed near noon, with the Nasdaq up nearly 200 points, led by tech names....

4d ago

Vaxcyte rises 33.7%

Vaxcyte (PCVX) is up 33.7%, or $19.05 to $75.53. Published first on TheFly – the ultimate source for...

4d ago

PCVX

Vaxcyte rises 46.4%

Vaxcyte (PCVX) is up 46.4%, or $26.19 to $82.67. Published first on TheFly – the ultimate source for...

4d ago

PCVX

Vaxcyte data hit ‘blue-sky’ case, says Jefferies

After Vaxcyte (PCVX) announced topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating its VAX-31 31-valent...

4d ago

PCVX

Vaxcyte can trade in $90-$100 range on data, says Mizuho

Mizuho says Vaxcyte’s (PCVX) VAX-31 Phase 3 data this morning are “very clean” and “near best-case scenario.” Mizuho...

4d ago

PCVX

Vaxcyte Announces Positive Phase 3 Results for VAX-31

An update from Vaxcyte ( ($PCVX) ) is now available. On October 5, 2026, Vaxcyte reported positive topline...

4d ago

PCVX

Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline

Vaxcyte ( ($PCVX) ) just unveiled an update. On August 31, 2026, Vaxcyte appointed David McAvoy as Chief...

1M ago

PCVX

Analyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts

Joseph Stringer, an analyst from Needham, reiterated the Buy rating on Vaxcyte. The associated price target remains the...

2M ago

PCVX

5VA FAQ

What was Vaxcyte, Inc.’s price range in the past 12 months?

Vaxcyte, Inc. lowest stock price was €33.20 and its highest was €76.50 in the past 12 months.

What is Vaxcyte, Inc.’s market cap?

Vaxcyte, Inc.’s market cap is €8.87B.

When is Vaxcyte, Inc.’s upcoming earnings report date?

Vaxcyte, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 31 days.

How were Vaxcyte, Inc.’s earnings last quarter?

Vaxcyte, Inc. released its earnings results on Aug 05, 2026. The company reported -€1.755 earnings per share for the quarter, beating the consensus estimate of -€1.831 by €0.077.

Is Vaxcyte, Inc. overvalued?

According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vaxcyte, Inc. pay dividends?

Vaxcyte, Inc. does not currently pay dividends.

What is Vaxcyte, Inc.’s EPS estimate?

Vaxcyte, Inc.’s EPS estimate is -1.9.

How many shares outstanding does Vaxcyte, Inc. have?

Vaxcyte, Inc. has 148,805,280 shares outstanding.

What happened to Vaxcyte, Inc.’s price movement after its last earnings report?

Vaxcyte, Inc. reported an EPS of -€1.755 in its last earnings report, beating expectations of -€1.831. Following the earnings report the stock price went down -3.347%.

Which hedge fund is a major shareholder of Vaxcyte, Inc.?

Currently, no hedge funds are holding shares in DE:5VA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vaxcyte Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.57%

Trailing 12-Months

Asset Growth

-5.06%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Vaxcyte, Inc.

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Vaxcyte (5VA) Earnings & Revenues

Historic Earnings Reports

5VA Stock 12 Month Forecast

Average Price Target

€105.77

▲(99.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"€28","87":"€87","146":"€146","57.5":"€57.5","116.5":"€116.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145.02760044,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€145.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.76782823500001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€105.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.730491,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€66.73</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,57.5,87,116.5,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.5,57.77135388,65.04270776,72.31406163999999,79.58541552,86.85676939999999,94.12812327999998,101.39947715999999,108.67083104,115.94218491999999,123.21353879999998,130.48489267999997,137.75624655999997,{"y":145.02760044,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.5,54.75137140269231,59.002742805384614,63.25411420807693,67.50548561076923,71.75685701346154,76.00822841615386,80.25959981884617,84.51097122153847,88.76234262423077,93.01371402692308,97.2650854296154,101.51645683230771,{"y":105.76782823500001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.5,51.748499307692306,52.99699861538461,54.245497923076925,55.49399723076923,56.74249653846154,57.990995846153844,59.23949515384615,60.48799446153846,61.73649376923077,62.984993076923075,64.23349238461539,65.48199169230769,{"y":66.730491,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.5,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >